日本語のみで絞り込む
LMTX is a tau aggregation inhibitor (TAI), which aims to reduce levels of the abnormal tau protein. The active component of LMTX, methylthioninium chloride (MTC) ...
2024/5/10 -TRx0237 (LMTX™) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal ...
TauRx Reports First Phase 3 Results for LMTX® Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials.
2016/6/26 -... LMTX™, TRx0237, TauRx Therapeutics Ltd., Republic of Singapore), a second-generation TAI for the AD treatment. TRx0237 shares the same ...
TRx 0237 (LMTX™) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. It is ...
Since April 2019, there is a new implementation of ConTeXt, named ConTeXt LMTX. It is tuned for LuaMetaTeX, the lean and mean successor of the LuaTeX engine ...
LMTX edit. LMTX is a stable anhydrous reduced form of methylthioninium chloride. : fig 1A (Chloride is replaced by bromide or methanesulfonate.) One of ...
2016/7/28 -The UK public woke up this morning to a series of headlines about phase III trial results of a potential Alzheimer's drug called LMTX (also ...
2016/7/27 -LMTX, which is TauRx's only drug, is a derivative of methylene blue, a dye. It is also being tested as a treatment for frontotemporal dementia, ...
Discover our innovative pipeline for Alzheimer's and other neurodegenerative diseases. Learn more about our current drug candidates and ongoing clinical…